'Imatinib in COVID19 patients (INVENT COVID): a RCT Flashcards
What is the difference between traditional and stratified medicine?
- For traditional medicine, a group with the same disease gets administred the same drug. However, the characteristics of the people within this group can differ. Resulting in only some experiencing benefit from the drug, some experiencing no benefit and even some that will experience adverse events from the drug.
- For stratified medicine, patients can be grouped by their characteristics (e.g. disease subtype, risk profile, demographics, etc.). These now different patient groups get administred a more targeted treatment, resulting in every patient group benefiting from the treatment.
What are (minimally invasive) markers/parameters of vascular permeability?
- Angiopoietin-2
- Radio-actively labelled protein
- Thermodilution method
- CT scan
When does vascular/endothelial permeability peak in the course of COVID?
At an earlier stage of COVID-19, different types of cells of the lungs are infected, which results in an inflammatory response. With the release of cytokines by different immune cells, the inflammatory response is enhanced. Because of this, vascular permeability increases. This process happens at a later-stage of COVID-19.
What is the best timeframe for pharmacological interference?
Before the pathophysiology has started, so before infection of the lungs and pulmonary edema has occured(?)
How does endothelial permeability relate to clinical heterogeneity?
That it is different for every person how they will respond to COVID-19 infection. This means that every person’s immune systems reacts differently and that also (the degree of) endothelial permeability differs per person -> clinical heterogeneity.
How can heterogeneity in ARDS clinical trials be reduced?
Using physiological, radiographic, and biological criteria to select patients for both phase 2 and 3 trials.
